Description
Product Specifications
Form: Lyophilized peptide powder
Strength: Add the product-specific strength
Peptide Length: 39 amino acid residues
Peptide Classification: Synthetic lipidated GIPR/GLP-1R/GCGR multi-receptor research peptide
Modified Peptide Sequence: Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-α-Me-Leu-Leu-Asp-Lys-Lys*-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂
Short Sequence: Y-Aib-QGTFTSDYSI-α-Me-Leu-LDK-K*-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂
Non-Natural Residues: Aib at positions 2 and 20 and α-methyl-L-leucine at position 13
Lipid Modification: Lys17 side chain modified with a C20 fatty di-acid through a γ-Glu/AEEA-containing linker
C-Terminal Modification: Amidated
Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: Approximately 4731.36 g/mol
CAS Number: 2381089-83-2
Purity: ≥99%, where confirmed through batch-specific HPLC analysis
Appearance: White to off-white lyophilized peptide powder
Intended Use: Laboratory research and analytical applications only
FDA GSRS reports Retatrutide as an electrically neutral defined structure with molecular formula C₂₂₁H₃₄₂N₄₆O₆₈ and molecular weight 4731.36. PubChem independently associates Retatrutide and LY3437943 with CAS 2381089-83-2.
The detailed 39-residue sequence and modification pattern are also supported by batch analytical documentation showing Aib residues, α-methyl-leucine, Lys-linked C20 diacid modification, and C-terminal amidation.
Research Applications
Analytical characterization using HPLC, UPLC, and LC-MS workflows
In vitro investigation of GIP receptor-binding behavior
In vitro investigation of GLP-1 receptor-binding behavior
In vitro investigation of glucagon receptor-binding behavior
Evaluation of multi-receptor intracellular signaling under controlled assay conditions
Structure-activity analysis of engineered multi-receptor peptide ligands
Characterization of non-natural amino acid substitutions
Analysis of Lys17 lipid-linked side-chain architecture
Peptide identity, purity, molecular weight, and structural integrity assessment
Comparative evaluation of Retatrutide and structurally related peptide research compounds
Stability profiling under controlled temperature, pH, buffer, and storage conditions
Quality Documentation
A batch-specific Certificate of Analysis and applicable analytical documentation should be available for each lot. Verify peptide identity, exact sequence, Aib substitutions, α-methyl-leucine residue, Lys17 lipidation, C-terminal amidation, purity, molecular weight, counterion content, formulation details, and batch information against the records supplied with the individual product.
Retatrutide is substantially more structurally complex than a conventional unmodified peptide. Its molecular identity includes the non-natural amino acids, C20 fatty di-acid conjugate, linker architecture, and terminal amidation in addition to the underlying peptide backbone.
Salt or counterion-containing materials should be distinguished from the defined parent structure. PubChem also contains records associated with Retatrutide sodium-related preparations, so the material's actual counterion status should be confirmed from lot-specific analytical records rather than inferred solely from the product name.
Batch-specific HPLC and mass-spectrometric documentation should be treated as the final reference for product identity and analytical specifications.
For Laboratory Research Use Only
This product is intended exclusively for controlled laboratory and in vitro research. Not for human or veterinary use. Not for diagnostic, therapeutic, clinical, cosmetic, or household applications.

Reviews
There are no reviews yet.